This article has Open Peer Review reports available.
Oesphageal Stenting for palliation of malignant mesothelioma
© Akowuah and Rahamim; licensee BioMed Central Ltd. 2008
Received: 01 January 2007
Accepted: 25 January 2008
Published: 25 January 2008
Dyspahgia in patients with malignant mesothelioma is usually due to direct infiltration of the eosophagus by the tumour. It can be distressing for the patient and challenging for the physician to treat. We describe three cases in which this condition has been successfully palliated with self expanding esophageal stents.
The incidence of malignant pleural mesothelioma (MM) is rising rapidly in many countries and it continues to be a challenging clinical problem. Dysphagia complicating the disease is due to direct esophageal extension of the tumor and has been infrequently described [1–3]. In these cases, dysphagia has been a late complication and usually a terminal event. There is only one reported case of attempted surgical palliation with an endo-oesophageal tube placed under general anesthetic via a gastrotomy .
Over recent years, we have acquired extensive experience in the use of endoluminal self expanding metal stents (SEMS) via endoscopy of the oesophagus for palliation of esophageal malignancy and for benign strictures. In this report, we describe a series of patients with MM presenting with dyspahgia and treated by esophageal SEMS.
A 79 year old gentleman with a history of previous asbestos exposure presented with left sided pleural effusion in February 2000. He underwent VATS drainage of the effusion and a pleural biopsy which confirmed a diagnosis of MM (epitheliod type). He was treated by radiotherapy and remained well till July 2001 when he presented with dysphagia. CT confirmed esophageal extension of the tumour and at endoscopy narrowing of the esophagus from 15 to 30 cm was observed. A 15 cm SEM was inserted. The SEM was deployed in a satisfactory position but only had a slit like opening therefore we decided to perform balloon dilatation within the stent.
Balloon dilatation was performed under fluoroscopic guidance. A 50 mm balloon was positioned across the narrowed region of the stent. The balloon was inflated up to 3 atmospheres pressure until a satisfactory lumen within the stent was observed. A water soluble contrast swallow was performed after the procedure.
The patient was discharged and was well for 4 months before presenting again with dysphagia and weight loss. At endoscopy, the previous stent was patent, however a new section of oesophagus distal to the stent was narrowed. This was dilated with to 17 mm with Savary-Gillard dilators and a new SEMS placed from inside the original stent extending into the stomach. He was discharged from hospital but died 8 months later without any further dysphagia.
A 67 year old gentleman, with a history of previous asbestos exposure, presented with weight loss dyspnoea and left sided chest pain in September 2002. Chest x-ray showed a left sided pleural effusion. CT confirmed the effusion and pleural thickening extending into the mediastinum and revealed para cardiac lymph nodes. In December 2002, He had a bronchoscopy and VATS drainage of the effusion and talc pleurodesis. Pleural fluid cytology and pleural biopsies confirmed sarcomatoid MM.
He was treated with radiotherapy to the chest wall and remained well until June 2003 when he presented with progressive dysphagia. CT showed tumour invading the esophagus and endoscopy showed extrinsic compression of the oesophagus from 30 to 40 cm. A 10 cm SEM was inserted. He survived a further 6 months with good level of activity and no stent related complications.
Technically, the use of SEMS in the setting of malignant pleural mesothelioma presents several unique challenges. Firstly because there is usually infiltration of long segments of the oesophagus, long stents and occasionally multiple SEMS may be required. Secondly because the oesophagus is infiltrated externally and becomes contiguous with a large tumour mass throughout the mediastinum, esophageal expansion during stent deployment is limited. We have usually attempted to treat this by balloon dilatation of the stent after it has been deployed.
Finally because the underlying disease is progressive, further stenting of previously unaffected section of the esophagus through patent SEMs may be required.
Dysphagia is a rare but recognized complication of malignant mesothelioma. It is usually a very late feature and is usually a terminal event. With more aggressive treatment for malignant mesothelioma, and patients living longer with the diagnosis, this complication may become more common. The average length of survival after diagnosis with malignant mesothelioma in symptomatic patients is 14.7 months [5, 6]. The group of patients in this report lived for 6, 8, and 2 months after stent placement. They had a good quality of life and few stent related complications. After stent insertion all 3 patients gained weight indicating that rapid weight loss was not necessarily due to metastatic dissemination of tumour but may in part be due to local effects.
In conclusion, this report shows that active treatment of dysphagia in patients with malignant mesothelioma is beneficial to patients even in the presence of disseminated disease and should therefore be considered in all cases.
- Ratzer ER, Pool JL, Melamed MR: Pleural mesotheliomas. Clinical experiences with thirty-seven patients. Am J Roentgenol Radium Ther Nucl Med. 1967, 99 (4): 863-80.View ArticlePubMedGoogle Scholar
- Johnson CE, Wardman AG, McMahon MJ, Cooke NJ: Dysphagia complicating malignant mesothelioma. Thorax. 1983, 38 (8): 635-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Dorward AJ, Stack BH: Diffuse malignant pleural mesothelioma in Glasgow. Br J Dis Chest. 1981, 75 (4): 397-402. 10.1016/0007-0971(81)90027-9.View ArticlePubMedGoogle Scholar
- Lockwood CA, Jones HW, Foote CK, Turner MJ: Dysphagia due to mesothelioma infiltrating the oesophagus: palliative treatment. J R Soc Med. 1989, 82 (3): 168-PubMedPubMed CentralGoogle Scholar
- Simmons DT, Baron TH: Endoluminal palliation. Gastrointest Endosc Clin N Am. 2005, 15 (3): 467-84. 10.1016/j.giec.2005.03.005. viiiView ArticlePubMedGoogle Scholar
- Whitwell F, Rawcliffe RM: Diffuse malignant pleural mesothelioma and asbestos exposure. Thorax. 1971, 26 (1): 6-22.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.